文献速递MDS 与骨髓增殖性肿瘤

美国骨髓增殖性肿瘤的发病率、患病率与生存结局:SEER数据库2000-2021年分析

Incidence, prevalence, and survival outcomes of patients with myeloproliferative neoplasms in the United States: a Surveillance, Epidemiology, and End Results (SEER) database analysis, years 2000-2021.
PubMed 文献 · Leukemia · 2026-08-31

基于SEER-17登记数据库分析2000-2021年确诊的63,242例成人MPN患者,ET、PV、PMF和CML的总体发病率分别为1.8、1.7、0.5和0.7/10万人年。PMF的5年相对生存率从2009年的50.9%提高至2016年的60.6%,各亚型中位总生存期ET为152个月、PV为150个月、PMF为48个月、CML为202个月。

要点

  • ET和PV发病率最高,分别为1.8和1.7/10万人年,PMF最低为0.5/10万人年。
  • PMF的5年相对生存率从2009年50.9%升至2016年60.6%,呈持续改善趋势。
  • 各MPN亚型中位总生存期:CML 202个月、ET 152个月、PV 150个月、PMF 48个月。

核心结论

  • ET、PV、PMF和CML的发病率分别为1.8、1.7、0.5和0.7/10万人年,PMF生存近年持续改善。
  • 各亚型中位总生存期ET 152个月、PV 150个月、PMF 48个月、CML 202个月。

研究设计与样本

  • 基于NCI的SEER-17登记数据库,纳入2000至2021年确诊的成人MPN患者共63,242例。
  • 亚型分布:ET 24,172例、PV 23,456例、PMF 6,131例、CML 9,483例。

主要发现

  • ET、PV、PMF和CML的总体发病率分别为1.8、1.7、0.5和0.7/10万人年。
  • ET、PV和MF的发病率随年龄增长而升高,多数病例见于50岁之后。
  • PMF的5年相对生存率2009年为50.9%、2013年为57.4%、2016年为60.6%。
  • 中位总生存期ET为152个月、PV为150个月、PMF为48个月、CML为202个月。
  • 年龄增长与各MPN亚型的不良生存相关,且存在重要的种族和性别差异。

临床怎么用

  • 可为MPN各亚型的预后咨询和随访策略提供基于人群的生存参考数据。
  • PMF患者生存改善趋势支持当前治疗策略的持续优化。
  • 应关注年龄、种族和性别差异对MPN生存的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myeloproliferative Neoplasms (MPNs) are rare hematologic neoplasms. The epidemiology and outcomes of these rare neoplasms warrant an update considering new diagnostic tools and advances in treatment options. NCI's Surveillance, Epidemiology and End Results (SEER)-17 registries were interrogated to analyze adult patients diagnosed with MPN [ICD-O-3 codes: polycythemia vera (PV) 9950/3, essential thrombocythemia (ET) 9962/3, primary myelofibrosis (PMF) 9961/3 and chronic myeloid leukemia (CML) 9875/3] during the years 2000 to 2021. Data of 63,242 (ET, n = 24,172; PV, n = 23,456; PMF, n = 6131; CML, n = 9483) patients were analyzed. The overall incidence rate (IR) for ET, PV, PMF and CML was 1.8, 1.7, 0.5 and 0.7 per 100,000 person-years, respectively. The incidence of ET, PV, and MF increased with age, and the majority of cases were seen after the age of 50. 5-year Relative Survival (RS) for PMF was 50.9% in 2009, to 57.4% in 2013 and 60.6% in 2016. The median overall survival (OS) was 152 months for ET, 150 months for PV, 48 months for PMF, and 202 months for CML. Advancing age was associated with adverse survival across MPN subtypes. Survival of patients with PMF continues to improve over recent years. Important racial and gender variations exist, which were noted in our study.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Singhal S, Mishra R, Arora S, et al. Incidence, prevalence, and survival outcomes of patients with myeloproliferative neoplasms in the United States: a Surveillance, Epidemiology, and End Results (SEER) database analysis, years 2000-2021. Leukemia. 2026. PMID: 42675140. doi:10.1038/s41375-026-03124-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。